Curis (United States)

Recent papers from Curis (United States)

1. The role of artificial intelligence in pharmacovigilance for rare diseasesExpert Opinion on Drug Safety · 2025
2. Ovarian Stimulation Effects on Ghrelin Secretion and Reproductive PotentialClinical Endocrinology · 2024
3. Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993European Journal of Nuclear Medicine and Molecular Imaging · 2024
4. Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL).Journal of Clinical Oncology · 2024
5. A phase 1 single-arm, open-label study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in patients (pts) with acute myeloid leukemia (AML) in complete response (CR) with measurable residual disease (MRD).Journal of Clinical Oncology · 2024
6. Predictive biomarkers of response to the IRAK4/FLT3 inhibitor emavusertib in hematological malignancies.Journal of Clinical Oncology · 2024
7. Preliminary safety, efficacy and molecular characterization of emavusertib (CA-4948) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation (FLT3m).Journal of Clinical Oncology · 2024
8. Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor in patients with stage III and IV melanomaFrontiers in Oncology · 2024
9. Abstract CT150: Trial in progress: A phase 1b single-arm, open-label, study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in acute myeloid leukemia patients in complete response with measurable residual diseaseCancer Research · 2024
10. Abstract 2902: CA-4948 (emavusertib) improves treatment response of preclinical metastatic brain melanoma to anti-PD-1 immune checkpoint blockadeCancer Research · 2024
11. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignanciesFrontiers in Immunology · 2023
12. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlightsFrontiers in Oncology · 2023
13. An autoantigen-ome from HS-Sultan B-Lymphoblasts offers a molecular map for investigating autoimmune sequelae of COVID-19Australian Journal of Chemistry · 2023
14. Data from Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened2023
15. VISTA expression and patient selection for immune-based anticancer therapyFrontiers in Immunology · 2023
16. Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK InhibitorsJournal of Clinical Medicine · 2023
17. 761 Pharmacokinetic and pharmacodynamic data from a phase 1 study of CI-8993 Anti-VISTA antibody in patients with advanced solid tumorsRegular and Young Investigator Award Abstracts · 2022
18. Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome.Journal of Clinical Oncology · 2022
19. S129: Takeaim Leukemia- A Phase 1/2a Study of the Irak4 Inhibitor Emavusertib (Ca-4948) as Monotherapy or in Combination With Azacitidine or Venetoclax in Relapsed/Refractory Aml or MDSHemaSphere · 2022
20. Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancerJournal of Hematology & Oncology · 2022